glp 1 agonist retatrutide Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA Retatrutide Benefits: 24% Weight Loss

You do not need to memorize a speech, but you do need to remember three things: your specific health goals (not "lose weight" but "reduce my A1c from 6.1 to below 5.7 and lose enough weight to reduce my blood pressure medication"), the treatments you have already tried, and your awareness of GLP-1 side effects and commitment to managing them

In addition, those using a GLP-1 RA had a 16% lower MACE risk than those who did not use a GLP-1

Wu Q, Li D, Huang C, et al

Our personalized approach to weight management helps you feel confident and healthier, enhancing your appearance and vitality

GLP-1 receptor agonists and DPP4-inhibitor direct the T2DM therapies